Actively Recruiting

Phase 2
Age: 30Years +
All Genders
NCT07024693

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Led by Design Therapeutics, Inc. · Updated on 2025-12-29

28

Participants Needed

2

Research Sites

69 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.

CONDITIONS

Official Title

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy

Who Can Participate

Age: 30Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant is scheduled to undergo keratoplasty for Fuchs Endothelial Corneal Dystrophy
  • 30 years of age or older
  • Documented diagnosis of FECD in the study eye
  • Positive TCF4 allele 18.1 CTG expansion in at least one allele
  • Able to provide signed informed consent
Not Eligible

You will not qualify if you...

  • Any significant ocular or medical condition in the study eye that could affect study results
  • Any serious medical, psychiatric, or nonmedical disorder that could increase risk or interfere with participation
  • Need for FECD treatments like Muro 128 during the study (unless washed out 24 hours before baseline)
  • Use of topical corticosteroids in the study eye
  • Use of Rhopressa, Rocklatan, or other ocular Rho Kinase inhibitors
  • Known allergy or hypersensitivity to study treatments or agents used
  • Use of contact lenses in the study eye within 7 days before baseline or planned use during study
  • Participation in another investigational study within 30 days before screening
  • Female participants who are pregnant, planning pregnancy, or breastfeeding
  • Unwillingness to follow contraceptive requirements as per protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

DTX-168-201 Study Site

Indianapolis, Indiana, United States, 46260

Actively Recruiting

2

DTX-168-201 Study Site

Grand Rapids, Michigan, United States, 49546

Actively Recruiting

Loading map...

Research Team

M

Mark Daniels

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy | DecenTrialz